| Name | Title | Contact Details |
|---|
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
Industrial Facilities Design Inc is a Hopkinton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At iA, we partner with our customers to transform pharmacy by deepening the patient-pharmacist relationship, enhancing patient safety and increasing operational efficiency.